| 1 |
Zhang Z, Wang FS. Stem cell therapies for liver failure and cirrhosis[J]. J Hepatol, 2013, 59(1):183-185.
|
| 2 |
da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues[J]. J Cell Sci, 2006, 119(Pt 11):2204-2213.
|
| 3 |
El-Badawy A, Amer M, Abdelbaset R, et al. Adipose stem cells display higher regenerative capacities and more adaptable electro-kinetic properties compared to bone marrow-derived mesenchymal stromal cells[J]. Sci Rep, 2016, 6:37801.
|
| 4 |
Zheng Y, Huang C, Liu F, et al. Comparison of the neuronal differentiation abilities of bone marrowderived and adipose tissuederived mesenchymal stem cells[J]. Mol Med Rep, 2017, 16(4):3877-3886.
|
| 5 |
Zhang QZ, Nguyen AL, Yu WH, et al. Human oral mucosa and gingiva: a unique reservoir for mesenchymal stem cells[J]. J Dent Res, 2012, 91(11):1011-1018.
|
| 6 |
Semenov OV, Koestenbauer S, Riegel M, et al. Multipotent mesenchymal stem cells from human placenta: critical parameters for isolation and maintenance of stemness after isolation[J]. Am J Obstet Gynecol, 2010, 202(2):191-193.
|
| 7 |
Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood[J]. Blood, 2004, 103(5):1669-1675.
|
| 8 |
Pieper IL, Smith R, Bishop JC, et al. Isolation of mesenchymal stromal cells from peripheral blood of ST elevation myocardial infarction patients[J]. Artif Organs, 2017, 41(7):654-666.
|
| 9 |
Kim YS, Lee HJ, Yeo JE, et al. Isolation and characterization of human mesenchymal stem cells derived from synovial fluid in patients with osteochondral lesion of the talus[J]. Am J Sports Med, 2015, 43(2):399-406.
|
| 10 |
Kmiecik G, Spoldi V, Silini A, et al. Current view on osteogenic differentiation potential of mesenchymal stromal cells derived from placental tissues[J]. Stem Cell Rev Rep, 2015, 11(4):570-585.
|
| 11 |
Morandi F, Raffaghello L, Bianchi G, et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens[J]. Stem Cells, 2008, 26(5):1275-1287.
|
| 12 |
Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex[J]. Scand J Immunol, 2003, 57(1):11-20.
|
| 13 |
Rasmusson I, Ringden O, Sundberg B, et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells[J]. Transplantation, 2003, 76(8):1208-1213.
|
| 14 |
Poh KK, Sperry E, Young RG, et al. Repeated direct endomyocardial transplantation of allogeneic mesenchymal stem cells: safety of a high dose, ′off-the-shelf′，cellular cardiomyoplasty strategy[J]. Int J Cardiol, 2007, 117(3):360-364.
|
| 15 |
Zhao J, Wang J, Dang J, et al. A preclinical study-systemic evaluation of safety on mesenchymal stem cells derived from human gingiva tissue[J]. Stem Cell Res Ther, 2019, 10(1):165.
|
| 16 |
Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol, 2008, 8(12):958-969.
|
| 17 |
Raffaghello L, Bianchi G, Bertolotto M, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche[J]. Stem Cells, 2008, 26(1):151-162.
|
| 18 |
Brandau S, Jakob M, Hemeda H, et al. Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge[J]. J Leukoc Biol, 2010, 88(5):1005-1015.
|
| 19 |
Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data[J]. Nat Rev Immunol, 2007, 7(2):93-104.
|
| 20 |
Brown JM, Nemeth K, Kushnir-Sukhov NM, et al. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism[J]. Clin Exp Allergy, 2011, 41(4):526-534.
|
| 21 |
Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4＋CD25highFOXP3＋ regulatory T cells[J]. Stem Cells, 2008, 26(1):212-222.
|
| 22 |
Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J]. Blood, 2002, 99(10):3838-3843.
|
| 23 |
Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells[J]. Blood, 2005, 105(7):2821-2827.
|
| 24 |
Plumas J, Chaperot L, Richard MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells[J]. Leukemia, 2005, 19(9):1597-1604.
|
| 25 |
Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis[J]. Cell Stem Cell, 2012, 10(5):544-555.
|
| 26 |
Luz-Crawford P, Kurte M, Bravo-Alegria J, et al. Mesenchymal stem cells generate a CD4＋CD25＋Foxp3＋ regulatory T cell population during the differentiation process of Th1 and Th17 cells[J]. Stem Cell Res Ther, 2013, 4(3):65.
|
| 27 |
Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions[J]. Blood, 2006, 107(1):367-372.
|
| 28 |
Che N, Li X, Zhou S, et al. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation[J]. Cell Immunol, 2012, 274(1-2):46-53.
|
| 29 |
Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction[J]. Blood, 2008, 112(13):4991-4998.
|
| 30 |
Banas A, Teratani T, Yamamoto Y, et al. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury[J]. Stem Cells, 2008, 26(10):2705-2712.
|
| 31 |
Maumus M, Jorgensen C, Noel D. Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes[J]. Biochimie, 2013, 95(12):2229-2234.
|
| 32 |
Gazdic M, Arsenijevic A, Markovic BS, et al. Mesenchymal stem cell-dependent modulation of liver diseases[J]. Int J Biol Sci, 2017, 13(9):1109-1117.
|
| 33 |
Liu YC, Zou XB, Chai YF, et al. Macrophage polarization in inflammatory diseases[J]. Int J Biol Sci, 2014, 10(5):520-529.
|
| 34 |
Suk KT, Yoon JH, Kim MY, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial[J]. Hepatology, 2016, 64(6):2185-2197.
|
| 35 |
Li M, Lv Y, Chen F, et al. Co-stimulation of LPAR1 and S1PR1/3 increases the transplantation efficacy of human mesenchymal stem cells in drug-induced and alcoholic liver diseases[J]. Stem Cell Res Ther, 2018, 9(1):161.
|
| 36 |
Bruno S, Herrera SM, Pasquino C, et al. Human liver-derived stem cells improve fibrosis and inflammation associated with nonalcoholic steatohepatitis[J]. Stem Cells Int, 2019:6351091.
|
| 37 |
Chen L, Lu FB, Chen DZ, et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis[J]. Mol Immunol, 2018, 93:38-46.
|
| 38 |
Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial[J]. Hepatology, 2017, 66(1):209-219.
|
| 39 |
El-Ansary M, Abdel-Aziz I, Mogawer S, et al. Phase Ⅱ trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis[J]. Stem Cell Rev Rep, 2012, 8(3):972-981.
|
| 40 |
Amin MA, Sabry D, Rashed LA, et al. Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study[J]. Clin Transplant, 2013, 27(4):607-612.
|
| 41 |
Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients[J]. J Gastroenterol Hepatol, 2012, 27(Suppl 2):112-120.
|
| 42 |
Du Y, Li D, Han C, et al. Exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect liver against hepatic ischemia/ reperfusion injury via activating sphingosine kinase and sphingosine-1-phosphate signaling pathway[J]. Cell Physiol Biochem, 2017, 43(2):611-625.
|
| 43 |
Sun CK, Chang CL, Lin YC, et al. Systemic administration of autologous adipose-derived mesenchymal stem cells alleviates hepatic ischemia-reperfusion injury in rats[J]. Crit Care Med, 2012, 40(4):1279-1290.
|
| 44 |
Saat TC, van den Engel S, Bijman-Lachger W, et al. Fate and effect of intravenously infused mesenchymal stem cells in a mouse model of hepatic ischemia reperfusion injury and resection[J]. Stem Cells Int, 2016:5761487.
|
| 45 |
Peng Y, Chen X, Liu Q, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5＋ regulatory B cells producing interleukin 10[J]. Leukemia, 2015, 29(3):636-646.
|
| 46 |
Gao L, Zhang Y, Hu B, et al. Phase Ⅱ multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation[J]. J Clin Oncol, 2016, 34(24):2843-2850.
|
| 47 |
Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase Ⅱ study[J]. Lancet, 2008, 371(9624):1579-1586.
|
| 48 |
Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase Ⅰ study on 40 adult and pediatric patients[J]. Biol Blood Marrow Transplant, 2014, 20(3):375-381.
|